Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

How Compass is developedGive feedback

ALS Untangled supports testing butyrates in people with ALS

Original source

ButyratesALSUntangled · 21 March 2022 (opens in a new tab)

ALS Untangled says butyrates have plausible mechanisms and positive preclinical findings related to slowing ALS progression. It notes that one trial of sodium phenylbutyrate combined with tauroursodeoxycholic acid suggested slower progression and longer survival, but the individual contribution of sodium phenylbutyrate is unclear. The group supports clinical trials but does not recommend a butyrate as treatment yet.

Why this matters

This supports further research for people living with ALS, but it does not establish that butyrates help patients or change treatment now. The review says butyrates appear reasonably safe for use in humans, while noting that more targeted trial evidence is needed.

Limitations and context

This is an independent expert review, not a new clinical trial. The evidence includes preclinical studies and one combination-treatment trial, so it does not show which component produced the observed effect. The review does not recommend butyrates as treatment at this stage.

Summarised by Compass 9 August 2026

This summary was generated by AI from the source listed above. It is not medical advice, so read the original source for anything that affects your care.

Relevant to you?